Flash Finance

Caplin Point Laboratories LimitedCAPLIPOINTCorporate

Healthcare Drug Manufacturers - Specialty & Generic Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹2,301.30
MCap ₹17,493 Cr · P/E 25.8
Caplin Point Laboratories Limited — Stock analysis & AI research Caplin Point Laboratories Limited — Seasonality — best & worst months Caplin Point Laboratories Limited — Technical indicators & charts Caplin Point Laboratories Limited — Technical setup — score, trend, support & resistance Caplin Point Laboratories Limited — Live exchange announcements
📋 High ROCE Stocks📋 High Operating Margin Stocks📋 High Interest Coverage Stocks📋 Low Debt Stocks📋 High Promoter Holding Stocks📋 Small Cap Stocks List 📈 RSI Oversold Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹610 Cr
Sales · Jun 2026
+19.6% YoY
₹213 Cr
Operating Profit · Jun 2026
+20.1% YoY
35.0%
OPM % · Jun 2026
+0.6% YoY
₹179 Cr
Net Profit · Jun 2026
+18.8% YoY
₹23.27
EPS · Jun 2026
+15.8% YoY

📝 Caplin Point Laboratories Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Caplin Point Laboratories Limited reported revenue of ₹610 crore for the quarter ended June 2026 (Q1 FY27), up 19.6% from ₹510 crore in the same quarter last year, and up 1.7% sequentially over the March 2026 quarter.

Net profit rose 18.8% year-on-year to ₹179 crore, from ₹151 crore. Earnings per share (EPS) came in at ₹23.27.

Operating profit stood at ₹213 crore — an operating margin (OPM) of 35.0%, compared with 34.8% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Caplin Point Laboratories Limited posted revenue of ₹2,187 crore, a growth of 12.9% over FY25, with a net profit of ₹650 crore (up 20.2% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹2,287 crore with a net profit of ₹678 crore.

Valuation snapshot

At the current price of ₹2,301.30, CAPLIPOINT has a market capitalisation of ₹17,493 crore and a trailing P/E of about 25.8.

Within the Drug Manufacturers - Specialty & Generic industry, it is the 23rd-largest of the 31 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 70.57%, foreign institutional investors (FIIs) 5.75%, domestic institutional investors (DIIs) 2.49%, public shareholders 21.18% of Caplin Point Laboratories Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹17,493 Cr
Current Price ?
₹2,301.3
P/E ?
25.79below ind
Industry P/E ?
35.00
P/B ?
4.88
P/S ?
7.65
P/FCF ?
63.61
Enterprise Value ?
₹17,498 Cr
EV/EBITDA ?
21.96
PEG ?
1.29
Earnings Yield ?
4.1%
Dividend Yield ?
0.26%
Profitability & Returns
Sales (TTM) ?
₹2,287 Cr
OPM ?
34.8%
Profit after tax (TTM) ?
₹678 Cr
EPS (TTM) ?
₹89.24
ROCE ?
25.0%
ROE ?
18.9%
ROA ?
16.8%
Growth
Sales — latest qtr ?
₹610 Cr
PAT — latest qtr ?
₹179 Cr
YoY qtr sales growth ?
19.6%
YoY qtr profit growth ?
18.8%
Sales growth (3y) ?
14%
Sales growth (5y) ?
16%
Profit growth (3y) ?
20%
Profit growth (5y) ?
22%
Financial Health
Debt ?
₹5 Cr
Debt to Equity ?
0.00
Interest Coverage ?
2,024.2
Current Ratio ?
N/A
Ownership
Promoter holding ?
70.57%
Change in promoter holding ?
0.01%
Pledged percentage ?
N/A
Market
Return 3 months ?
-12.0%
Return 6 months ?
30.0%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 372389395410436453459483493502510534543600610 +19.6% +1.7%
Operating Profit 109124127137142145152165162168178189190204213 +20.1% +4.6%
Other Income 141112211717192131262330342834 +44.8% +19.8%
Interest 000000000000000 +0.0% —
Depreciation 111111121416161716171618191922 +32.7% +13.8%
Profit Before Tax 112124127146145146154168177177184201204213225 +22.1% +5.7%
Net Profit 97101104116120121125131140145151160166173179 +18.8% +3.5%
EPS 12.8413.4513.6215.1315.4316.0116.3217.2218.2818.7620.1020.3221.5622.3823.27 +15.8% +4.0%
OPM % 29.3% 31.8% 32.2% 33.4% 32.6% 32.0% 33.1% 34.1% 32.9% 33.5% 34.8% 35.4% 35.0% 34.0% 35.0% +0.6% +2.9%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹1,937 Cr ₹2,187 Cr ₹2,287 Cr +12.9%
Operating Profit ₹647 Cr ₹761 Cr ₹797 Cr +17.6%
OPM % 33.39% 34.79% 34.83% +4.2%
NPM % 27.92% 29.72% 29.65% +6.4%
Other Income ₹97 Cr ₹116 Cr ₹126 Cr +19.5%
Depreciation ₹66 Cr ₹73 Cr ₹78 Cr +10.3%
Interest ₹0 Cr ₹0 Cr ₹0 Cr -22.7%
EBIT ₹581 Cr ₹688 Cr ₹719 Cr +18.5%
PBT ₹677 Cr ₹802 Cr ₹843 Cr +18.5%
Tax ₹104 Cr ₹74 Cr ₹87 Cr -28.6%
Net Profit ₹541 Cr ₹650 Cr ₹678 Cr +20.2%
EPS ₹70.58 ₹84.36 ₹87.53 +19.5%
Material Cost ₹529 Cr ₹401 Cr ₹517 Cr -24.2%
Employee Cost ₹131 Cr ₹90 Cr ₹101 Cr -31.1%
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 15151515 +0.0%
Reserves 1,6492,0842,6193,571 +36.3%
Borrowings 2222192225 -97.7%
Other Liabilities 305380352454 +29.0%
Total Liabilities 2,1912,6983,2084,045 +26.1%
Fixed Assets 280453546605 +10.8%
CWIP 221117144209 +45.1%
Investments 281376590859 +45.6%
Other Assets 1,4101,7531,9282,373 +23.1%
Total Assets 2,1912,6983,2084,045 +26.1%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 271318432523 +21.1%
Cash from Investing Activity -216-319-333-582 -74.8%
Cash from Financing Activity -28-38-38-46 -21.1%
Net Cash Flow 27-3961-106 -273.8%
Free Cash Flow 78173241275 +14.1%
CFO/OP 81%77%86%88% +2.3%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 98117119138 +16.0%
Inventory Days 159183159181 +13.8%
Days Payable 84116103125 +21.4%
Cash Conversion Cycle 173184175194 +10.9%
Working Capital Days 144166174263 +51.1%
ROCE % 26%26%26%25% -3.8%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 % Chg
Promoters 70.56%70.57%70.57%70.57%70.57% +0.0%
FIIs 6.16%6.51%6.58%6.15%5.75% -6.5%
DIIs 2.22%2.10%2.05%2.14%2.49% +16.4%
Public 21.06%20.82%20.81%21.14%21.18% +0.2%
No. of Shareholders 94,16993,75393,70593,89694,385 +0.5%

⚖️ Peer comparison

Industry: Drug Manufacturers - Specialty & Generic · top 25 of 31 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUNPHARMA Sun Pharmaceutical ₹1,840.00 441,478 36.5 59,911 12,104 29.8% 20.2% 11.2% 5.1% 10.5% 27.0%
2 DIVISLAB Divi's Laboratories ₹9,235.00 245,160 83.8 11,230 2,925 35.3% 26.0% 12.8% 16.7% 27.8% 65.5%
3 TORNTPHARM Torrent Pharmaceuticals ₹4,931.00 187,559 87.1 15,723 2,156 33.0% 13.7% 21.4% 11.9% 54.8% 3.3%
4 ZYDUSLIFE Zydus Lifesciences ₹1,162.20 115,930 23.2 27,148 5,070 31.2% 18.7% 16.8% 12.0% 16.2% 14.5%
5 CIPLA Cipla ₹1,366.00 110,353 32.7 28,324 3,356 18.7% 11.8% 2.2% -26.7% 2.3% -39.2%
6 LAURUSLABS Laurus Labs ₹1,969.00 106,387 97.2 7,270 1,090 28.0% 15.0% 22.7% 147.9% 29.1% 123.9%
7 DRREDDY Dr. Reddy's ₹1,165.50 97,085 29.3 28,704 3,273 15.3% 11.4% -10.4% -25.8% -5.6% -69.2%
8 AUROPHARMA Aurobindo Pharma ₹1,679.80 96,652 26.2 34,935 3,711 20.3% 10.6% 6.1% 0.6% 16.3% 25.2%
9 LUPIN Lupin ₹2,095.00 95,797 17.9 27,958 5,356 31.5% 19.2% 23.1% 62.0% 31.9% 87.8%
10 MANKIND Mankind Pharma ₹2,280.00 94,174 46.1 14,738 2,067 26.0% 14.0% 16.3% -3.7% 12.9% 29.1%
11 GLENMARK Glenmark Pharmaceuticals ₹2,419.20 68,276 38.0 17,737 1,797 27.0% 10.1% -61.2% -67.4% 23.1% 927.9%
12 ALKEM Alkem Laboratories ₹5,243.50 62,694 29.1 15,081 2,187 20.1% 14.5% 13.5% 7.6% 10.9% -21.6%
13 ABBOTINDIA Abbott India ₹25,860.00 54,951 34.0 7,005 1,615 28.1% 23.1% 8.1% 9.7% 4.4% 17.2%
14 IPCALAB Ipca Laboratories ₹1,964.20 49,833 38.0 10,125 1,379 22.0% 13.6% 7.9% 55.0% 20.8% 82.2%
15 GLAND Gland Pharma ₹2,935.90 48,433 47.1 6,431 1,028 25.3% 16.0% -64.7% -48.4% 22.3% 96.7%
16 AJANTPHARM Ajanta Pharma ₹3,398.90 42,472 37.4 5,777 1,135 25.4% 19.7% 17.3% 14.8% 24.8% 30.9%
17 JBCHEPHARM J. B. ₹2,416.10 38,793 53.4 4,148 709 26.7% 17.1% 5.9% 7.5% -4.8% -30.7%
18 EMCURE EMCURE PHARMACEUTICALS ₹1,975.10 37,470 37.0 9,684 1,019 20.4% 10.5% 16.6% 33.1% 22.8% 36.0%
19 WOCKPHARMA Wockhardt ₹2,021.50 32,848 92.5 3,133 353 19.9% 11.3% -2.3% 342.1% 25.9% 199.1%
20 NEULANDLAB Neuland Laboratories ₹23,455.00 30,093 82.7 2,023 365 28.4% 18.0% 37.0% 40.2% 136.3% 666.0%
21 PPLPHARMA Piramal Pharma ₹211.50 28,024 113.5 9,206 247 11.0% 2.7% -3.1% -37.9% 17.4% -161.3%
22 GRANULES Granules India ₹885.60 21,945 32.8 5,633 663 22.7% 11.8% 19.7% 18.8% 22.0% 59.3%
23 CAPLIPOINT Caplin Point ₹2,752.60 20,923 31.4 2,287 678 34.8% 29.7% 12.9% 20.2% 19.6% 18.8%
24 ERIS Eris Lifesciences ₹1,358.00 18,820 29.0 3,230 666 35.2% 20.6% 8.2% 72.6% 13.0% 14.6%
25 ASTRAZEN AstraZeneca Pharma ₹6,755.00 16,888 99.6 2,432 170 9.4% 7.0% 32.7% 62.1% 29.7% -32.1%
❓ Frequently asked questions
What was Caplin Point Laboratories Limited's revenue in Q1 FY27?
Caplin Point Laboratories Limited reported revenue of ₹610 crore for the quarter ended June 2026 (Q1 FY27), up 19.6% from ₹510 crore in the same quarter last year, and up 1.7% sequentially over the March 2026 quarter.
What was Caplin Point Laboratories Limited's net profit in Q1 FY27?
Net profit rose 18.8% year-on-year to ₹179 crore, from ₹151 crore. Earnings per share (EPS) came in at ₹23.27.
What is CAPLIPOINT's market capitalisation and P/E ratio?
At the current price of ₹2,301.30, CAPLIPOINT has a market capitalisation of ₹17,493 crore and a trailing P/E of about 25.8.
Who owns Caplin Point Laboratories Limited? (shareholding pattern)
As of Jun 2026, promoters held 70.57%, foreign institutional investors (FIIs) 5.75%, domestic institutional investors (DIIs) 2.49%, public shareholders 21.18% of Caplin Point Laboratories Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI